Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222755 | 1.00 | LMNA (0.52) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL2346969 | 1.00 | LMNA (0.52) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL1223599 | 1.00 | LMNA (0.52) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL1219703 | 0.98 | LMNA (0.54) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| Methyl Alcohol SCHEMBL28137239 | 0.95 | LMNA (0.52) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL16628357 | 0.91 | LMNA (0.67) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL6249617 | 0.91 | LMNA (0.67) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL9620151 | 0.91 | LMNA (0.67) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL7912193 | 0.90 | LMNA (0.56) | LMNAKDM4ECNR1ADRA1ATDP1 | |
| SCHEMBL10580522 | 0.89 | LMNA (0.46) | LMNAKDM4ECNR1ADRA1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217560-B1 | SYNTHETIC ANALOGS OF SPHINGOLIPIDS | YISSUM RES DEV CO (IL) | 2016-01-27 | — | — | EP | claimed |
| US-20110034542-A1 | NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2011-02-10 | — | — | US | claimed |
| EP-2217560-A1 | NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) | 2010-08-18 | — | — | EP | claimed |
| WO-2009060457-A1 | NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2009-05-14 | — | — | WO | claimed |
| US-9340488-B2 | Synthetic analogs of sphingolipids | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2016-05-17 | — | — | US | disclosed |
| EP-2217560-B1 | SYNTHETIC ANALOGS OF SPHINGOLIPIDS | YISSUM RES DEV CO (IL) | 2016-01-27 | — | — | EP | disclosed |
| US-20150073003-A1 | NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-03-12 | — | — | US | disclosed |
| US-8962891-B2 | Synthetic analogs of sphingolipids | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2015-02-24 | — | — | US | disclosed |
| US-8962891-B2 | Synthetic analogs of sphingolipids | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2015-02-24 | — | — | US | disclosed |
| US-20110034542-A1 | NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2011-02-10 | — | — | US | disclosed |
| US-20110034542-A1 | NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2011-02-10 | — | — | US | disclosed |
| EP-2217560-A1 | NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060457-A1 | NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073003-A1 | NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS | CERS2, SGMS2, SGMS1 | LMNA 2702/4885KDM4E 2750/4885CNR1 298/4885 |
| US-20110034542-A1 | NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS | CERS2, SGMS2, SGMS1 | LMNA 2702/4885KDM4E 2750/4885CNR1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.